News News Jul 01, 2022 JIXING Announces the First Patient Enrollment in Phase 3 Study of Etripamil in China Jun 29, 2022 JIXING Announces Receipt of Clinical Trial Application Approval for China Cohort of Phase 3 Clinical Trial of Aficamten May 09, 2022 Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program Apr 20, 2022 JIXING Announces Leadership Transition Apr 13, 2022 LENZ Therapeutics and JiXing Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics Mar 31, 2022 JiXing Announces The Appointment Of Kun Wu As The Chief Commercial Officer Mar 21, 2022 JiXing Announces Receipt Of Clinical Trial Application Approval For OC-01 Nasal Spray Phase 3 Trial For The Treatment Of Signs And Symptoms Of Dry Eye Disease In China Mar 17, 2022 JiXing Presents Results Of China Phase 1 Study Of Aficamten At The 2022 American Society For Clinical Pharmacology And Therapeutics Annual Meeting Feb 16, 2022 JiXing Announces Receipt Of Breakthrough Therapy Designation For Aficamten In China Feb 04, 2022 Cytokinetics Announces FDA Acceptance Of New Drug Application For Omecamtiv Mecarbil For The Treatment Of Heart Failure With Reduced Ejection Fraction Dec 20, 2021 Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics Dec 3, 2021 Ji Xing completes Phase 1 study of aficamten, a potential next-generation cardiac myosin inhibitor, for patients with hypertrophic cardiomyopathy (HCM) Nov 19, 2021 JIXING Announces IND Approval for Phase 1 and Phase 3 Clinical Trials of Etripamil in Patients with Paroxysmal Supraventricular Tachycardia (PSVT) in China Aug 6, 2021 Chinese startup with Merck vet at the helm acquires rights to Oyster Point’s eye disease nasal spray Aug 5, 2021 Oyster Point Pharma Announces Exclusive License Agreement with JIXING Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China Jul 13, 2021 RTW Investments-Backed JIXING Pharmaceuticals Appoints Joseph Romanelli Chief Executive Officer May 17, 2021 Milestone Pharmaceuticals Announces Exclusive License Agreement with JIXING Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China Jul 14, 2020 RTW Investments, LP, JIXING Pharmaceuticals and Cytokinetics Enter Intro Strategic Financing Collaboration to Support the Development of CK-274 and Enter China View All News